Metformin may prevent lung cancer in smokers

Apr 19, 2010

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical trials.

Metformin decreases levels of insulin-like growth factor-1 (IGF-1) and circulating insulin, which is important in patients with . However, emerging research suggests may inhibit tumor growth as well.

"This well tolerated, FDA-approved was able to prevent tobacco-carcinogen induced lung tumors," said Phillip A. Dennis, M.D., Ph.D., senior investigator in the medical oncology branch of the National Cancer Institute.

For the current study, Dennis and colleagues treated mice with metformin for 13 weeks following exposure to a nicotine-derived nitrosamine (NNK), which is the most prevalent carcinogen in tobacco and a known promoter of lung tumorigenesis.

When given orally, metformin was well tolerated and reduced tumor burden by 40 percent to 50 percent. Dennis said levels of metformin reached in mice are readily achievable in humans.

Dennis and colleagues further evaluated the effects of metformin on a series of biomarkers for lung tumorigenesis and found that it inhibited mammalian target of rapamycin (mTOR), which promotes growth, by decreasing levels of circulating insulin and IGF-1. This effect was even more profound when metformin was administered to mice by injection, which reduced lung tumor burden by 72 percent.

Explore further: ACG: Recent increase in incidence of young-onset CRC

add to favorites email to friend print save as pdf

Related Stories

Diabetes drug slows early-onset puberty in girls

Jun 16, 2008

In young girls at risk of early puberty and insulin resistance, the diabetes drug metformin delayed the onset of menstruation and decreased the development of insulin resistance, a risk factor for type 2 diabetes, according ...

Penn researchers find diabetes drug kills some cancer cells

Aug 14, 2007

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53. Results from current studies in mice may result ...

FDA approves new diabetes treatment

Oct 17, 2006

The U.S. Food and Drug Administration has approved the use of Januvia tablets as the first in a new class of diabetes drugs.

Recommended for you

ACG: Recent increase in incidence of young-onset CRC

15 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments : 0